A phase II study of gemcitabine in combination with oxaliplatin as first line chemotherapy in patients with inoperable biliary tract adenocarcinoma

被引：0
|
作者：
Kim, H. [1 ]
Lee, S. [2 ]
Bae, S. [3 ]
Kim, C. [1 ]
Lee, N. [2 ,3 ]
Lee, K.
Park, S. [1 ]
Won, J. [1 ,2 ]
Hong, D.
Park, H. [2 ]
机构：
[1] Soonchunhyang Univ Hosp, Puchon, South Korea
[2] Soonchunhyang Univ Hosp, Seoul, South Korea
[3] Soonchunhyang Univ Hosp, Cheonan, South Korea
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71062-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页码：277 / 277
页数：1
相关论文
共 50 条
  • [21] Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas
    Jeeyun Lee
    Tae-You Kim
    Myung Ah Lee
    Myung Ju Ahn
    Hoon-Kyo Kim
    Ho Yeong Lim
    Nam Su Lee
    Byung Joo Park
    Jun Suk Kim
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 47 - 52
  • [22] Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas
    Lee, Jeeyun
    Kim, Tae-You
    Lee, Myung Ah
    Ahn, Myung Ju
    Kim, Hoon-Kyo
    Lim, Ho Yeong
    Lee, Nam Su
    Park, Byung Joo
    Kim, Jun Suk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (01) : 47 - 52
  • [23] Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer
    Takashi Sasaki
    Hiroyuki Isayama
    Yousuke Nakai
    Yukiko Ito
    Hirofumi Kogure
    Osamu Togawa
    Nobuo Toda
    Ichiro Yasuda
    Osamu Hasebe
    Iruru Maetani
    Naoki Sasahira
    Kenji Hirano
    Takeshi Tsujino
    Minoru Tada
    Masao Omata
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 1101 - 1107
  • [24] Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Ito, Yukiko
    Kogure, Hirofumi
    Togawa, Osamu
    Toda, Nobuo
    Yasuda, Ichiro
    Hasebe, Osamu
    Maetani, Iruru
    Sasahira, Naoki
    Hirano, Kenji
    Tsujino, Takeshi
    Tada, Minoru
    Omata, Masao
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (06) : 1101 - 1107
  • [25] A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract
    Karachaliou, Niki
    Polyzos, Aris
    Kentepozidis, Nikolaos
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vardakis, Nikolaos
    Kalykaki, Antonia
    Milaki, Georgia
    Georgoulias, Vassilis
    Androulakis, Nikolaos
    ONCOLOGY, 2010, 78 (5-6) : 356 - 360
  • [26] Gemcitabine plus oxaliplatin combination in patients with advanced biliary tract cancer
    Vattemi, E.
    Lusso, M.
    Pedersini, R.
    Baier, S.
    Cretella, E.
    Petric, M.
    Stocker, J.
    Graiff, C.
    ANNALS OF ONCOLOGY, 2007, 18 : VII111 - VII111
  • [27] Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers
    Clark, J. W.
    Meyerhardt, J. A.
    Sahani, D. V.
    Namasivayam, S.
    Abrams, T. A.
    Stuart, K.
    Bhargava, P.
    Blaszkowsky, L. S.
    Jain, S. R.
    Zhu, A. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer
    Oh, Sung Yong
    Lee, Gyeong-Won
    Kim, Hoon Gu
    Kim, Tae Hyo
    Kim, Hyun Jin
    Kang, Jung Hun
    CHEMOTHERAPY, 2008, 54 (06) : 479 - 484
  • [29] Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study
    Rubovszky, G.
    Lang, I.
    Ganofszky, E.
    Horvath, Z.
    Juhos, E.
    Nagy, T.
    Szabo, E.
    Szentirmay, Z.
    Budai, B.
    Hitre, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (18) : 3806 - 3812
  • [30] Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers
    Jensen, Lars H.
    Andersen, Rikke Fredslund
    Byriel, Lene
    Fernebro, Eva
    Jakobsen, Anders
    Lindebjerg, Jan
    Nottelmann, Lise
    Ploen, John
    Hansen, Torben F.
    ACTA ONCOLOGICA, 2020, 59 (03) : 298 - 301
12345